Back D, et al. - Researchers performed an integrated analysis of registrational studies utilizing the pangenotypic direct-acting antivirals (DAA) regimen of glecaprevir and pibrentasvir (G/P) to report adherence, effectiveness, safety and patient-reported outcomes (PROs) among patients with chronic hepatitis C virus (HCV) genotypes 1-6 infection with compensated liver disease (with or without cirrhosis) receiving G/P for 8, 12 or 16 weeks. They identified 2,522 patients who were receiving G/P; of these, 789 (31%) had a psychiatric disorder with the most common diagnoses being depression (64%; 506/789) and anxiety disorders (27%; 216/789). Patients with psychiatric disorders continuously displayed sustained virologic response at post-treatment week 12 rates >96% across individual psychiatric diagnoses and co-medication classes. Findings suggest that patients with chronic HCV infection and psychiatric disorders demonstrate high efficacy and good-tolerability for G/P treatment in addition to high adherence rates.